LYEL Stock Overview
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors.
Notes are coming soon
Lyell Immunopharma, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.27|
|52 Week High||US$8.74|
|52 Week Low||US$2.74|
|1 Month Change||-5.76%|
|3 Month Change||-40.76%|
|1 Year Change||-45.32%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-80.64%|
Recent News & Updates
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth PlansDec 15
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In GrowthSep 12
News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) ForecastsAug 08
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In GrowthApr 29
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business GrowthDec 31
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn SituationSep 17
|LYEL||US Biotechs||US Market|
Return vs Industry: LYEL underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: LYEL underperformed the US Market which returned -9.2% over the past year.
|LYEL Average Weekly Movement||10.8%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: LYEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: LYEL's weekly volatility (11%) has been stable over the past year.
About the Company
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications.
Lyell Immunopharma, Inc. Fundamentals Summary
|LYEL fundamental statistics|
Is LYEL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LYEL income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.04|
|Net Profit Margin||-660.62%|
How did LYEL perform over the long term?See historical performance and comparison